يعرض 481 - 500 نتائج من 23,096 نتيجة بحث عن '(( significant decrease decrease ) OR ( significant ((all decrease) OR (fold increases)) ))', وقت الاستعلام: 0.55s تنقيح النتائج
  1. 481
  2. 482

    Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> حسب Razia Rashid Rahil (22772495)

    منشور في 2025
    "…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …"
  3. 483

    Grade system. حسب Zhuoyang Xia (21354186)

    منشور في 2025
    الموضوعات:
  4. 484

    Literature search. حسب Zhuoyang Xia (21354186)

    منشور في 2025
    الموضوعات:
  5. 485

    Study characteristics. حسب Zhuoyang Xia (21354186)

    منشور في 2025
    الموضوعات:
  6. 486

    Flowchart of literature retrieval. حسب Zhuoyang Xia (21354186)

    منشور في 2025
    الموضوعات:
  7. 487

    Data extraction. حسب Zhuoyang Xia (21354186)

    منشور في 2025
    الموضوعات:
  8. 488
  9. 489
  10. 490
  11. 491
  12. 492

    Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx حسب Tengxiang Zhao (20749475)

    منشور في 2025
    "…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…"
  13. 493

    Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx حسب Tengxiang Zhao (20749475)

    منشور في 2025
    "…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…"
  14. 494
  15. 495
  16. 496
  17. 497
  18. 498
  19. 499
  20. 500

    Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque mean size. حسب Francesca Catto (21253435)

    منشور في 2025
    "…However, there is only a minimal effect on decreasing plaque size. (C) Short-term-treatment with a high dose of netoglitazone reveals a significant reduction in plaque size, especially observed in the hippocampus, striatum, thalamus, hypothalamus, midbrain, and hindbrain. …"